Squarepoint
CLSD

Squarepoint’s Clearside Biomedical CLSD Stock Holding History

Squarepoint’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-967
Closed -$18.4K – 5063
2024
Q3 		$18.4K Sell
967
-419
-30% -$7.15K ﹤0.01% 4027
2024
Q2 		$27K Buy
+1,386
New +$26.8K ﹤0.01% 3948
2021
Q4 		– Sell
-1,031
Closed -$93K – 3202
2021
Q3 		$93K Sell
1,031
-1,747
-63% -$154K ﹤0.01% 2686
2021
Q2 		$203K Sell
2,778
-3,926
-59% -$182K ﹤0.01% 2820
2021
Q1 		$248K Buy
+6,704
New +$337K ﹤0.01% 2556
2020
Q4 		– Sell
-2,189
Closed -$51K – 2961
2020
Q3 		$51K Buy
+2,189
New +$56.6K ﹤0.01% 2367
2018
Q4 		– Sell
-1,597
Closed -$147K – 1972
2018
Q3 		$147K Buy
1,597
+780
+95% +$92.7K ﹤0.01% 1832
2018
Q2 		$131K Buy
+817
New +$138K ﹤0.01% 1616

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's CLSD Position: Q4 2024 in Review

Squarepoint sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 967 shares — an estimated $18.4K sold.

Squarepoint first reported a position in CLSD in Q2 2018 and held it in 8 quarters. The position peaked at $248K in Q1 2021. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Squarepoint reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Squarepoint sold 967 Clearside Biomedical shares in Q4 2024, an estimated $18.4K.
  • Squarepoint first reported a position in Clearside Biomedical in Q2 2018 and held it in 8 quarters.
  • Squarepoint's Clearside Biomedical position peaked at $248K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.